Document is current
Any future updates will be listed below
-
Authors
Kudo, Kenichiro
Nishii, Kazuya
Makimoto, Go
Ishikawa, Nobuhisa
Tsubata, Yukari
Kodani, Masahiro
Fujimoto, Nobukazu
Yamasaki, Masahiro
Kubota, Tetsuya
Takigawa, Nagio
Fujitaka, Kazunori
Kanaji, Nobuhiro
Shibayama, Takuo
Itano, Junko
Ando, Chihiro
Hotta, Katsuyuki https://orcid.org/0000-0002-0112-0843
Kiura, Katsuyuki
-
Funding
Funding for this research was provided by:
the 2016 Chugoku Occupational Health Association Grant.
- License Information
-
More Information
Article History
Received: 23 July 2021
Accepted: 19 December 2021
First Online: 6 April 2022
Declarations
:
: EI received honoraria from AstraZeneca, Eli Lilly Japan, Boehringer Ingelheim, and Chugai Pharmaceutical. EI received additional research funding from Eli Lilly Japan and the MSD. Dr. Hotta reports personal fees from Pfizer, grants and personal fees from AstraZeneca, grants and personal fees from Chugai, grants and personal fees from Lilly, personal fees from Takeda, grants and personal fees from MSD, grants and personal fees from BMS, personal fees from Ono, personal fees from Nippon Kayaku, personal fees from Taiho, personal fees from Boehringer, outside the submitted work. Dr. Takigawa reports personal fees from AstraZeneca, grants and personal fees from Daiichi Sankyo Pharmaceutical, grants and personal fees from Chugai Pharmaceutical, grants and personal fees from Taiho Pharmaceutical, grants and personal fees from Pfizer, grants and personal fees from Boehringer Ingelheim, personal fees from Ono Pharmaceutical, personal fees from MSD, grants and personal fees from Eli Lilly, grants from Kyowa Hakko Kirin, grants from Nippon Kayaku, personal fees from Eisai, personal fees from Bristol-Myers Squibb, outside the submitted work. TM received honoraria from Takeda Pharmaceutical, Kyowa Hakko Kirin, Chugai Pharmaceutical, Novartis Pharmaceutical, Otsuka Pharmaceutical, Astellas Pharmaceutical, AsahiKASEI, Sumitomo Dainippon Pharmaceutical, Mochida Pharmaceutical, Bristol–Myers Squibb, Pfizer, Nippon Shinyaku, Janssen Pharmaceutical, Celgene, Eisai, Mundipharma, and Meiji Seika Pharma. TM also received research funding from Akeda Pharmaceutical and Kyowa Hakko Kirin. KO received research grants from Boehringer Ingelheim and Novartis Pharmaceuticals, Japan. KK received honoraria from Eli Lilly Japan, Nihon Kayaku, AstraZeneca, Daiichi Sankyo Pharmaceuticals, Chugai Pharmaceuticals, Taiho Pharmaceuticals, Boehringer Ingelheim, and Sanofi Aventis. All remaining authors declare no conflict of interest regarding this study.
: The ethics committee of all affiliated hospitals approved the study protocol (No. 1703-055; Institutional Review Board of Okayama University Hospital).
: Written informed consent was obtained from all patients.
: All the authors have consented to the submission of this original article.
